Eli Lilly not Seen at Risk from Indian Generic Glp-1s

Dow Jones00:03

1203 ET - Eli Lilly shouldn't face much risk from the possibility that Indian suppliers could sell cheap generic GLP-1 drugs in the U.S. and Europe beginning in 2031, UBS analysts write in a note. Their analysis of the supply chain suggests that Indian suppliers will be structurally capped at a 25% to 30% share of the global market for first-generation GLP-1s, facing delivery pen and fill/finish supply constraints. By the time Indian generics are on the market, the analysts write, most demand will have turned to improved next-generation GLP-1s. "We think LLY can beat numbers and has upside bias to consensus earnings estimates," the analysts write. "Much better and newer products will be available for consumers that will prefer higher efficacy/lower side effects." (elias.schisgall@wsj.com)

(END) Dow Jones Newswires

July 17, 2026 12:03 ET (16:03 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment